NR565 ADVANCED PHARMACOLOGY FUNDAMENTALS
FINAL 2026/2027 | Care of the Patient Exam | Chamberlain |
Pass Guaranteed - A+ Graded
SECTION 1: Foundations of Advanced Pharmacology (Q1-Q15)
Q1: A 68-year-old male with atrial fibrillation is started on amiodarone. He also takes
simvastatin 80 mg daily. The AGACNP recognizes that amiodarone inhibits CYP3A4 and
CYP2C9. Which adverse effect is most likely to occur from this drug-drug interaction?
A. Rhabdomyolysis from increased simvastatin levels
B. Hyperkalemia from decreased potassium excretion
C. Hypoglycemia from increased insulin sensitivity
D. Thrombocytopenia from bone marrow suppression
Correct Answer: A
Rationale: Amiodarone is a potent CYP3A4 inhibitor that increases simvastatin plasma
levels, significantly increasing the risk of statin-induced myopathy and rhabdomyolysis.
The simvastatin dose should be limited to 20 mg when used with amiodarone.
Amiodarone does not significantly affect potassium excretion, insulin sensitivity, or
platelet production via CYP inhibition.
Q2: A patient receives a drug with a half-life of 6 hours. Approximately how long will it
take to reach steady-state plasma concentration with consistent dosing?
A. 6 hours
B. 12 hours
C. 24 hours
D. 30 hours
,Correct Answer: D
Rationale: Steady-state concentration is typically reached after 4-5 half-lives. With a
6-hour half-life, steady state is achieved in 24-30 hours (4-5 × 6). This principle applies
to most drugs regardless of dosing interval, though loading doses can achieve
therapeutic levels more rapidly.
Q3: A 55-year-old female is prescribed warfarin 5 mg daily. She begins taking rifampin
for tuberculosis treatment. What is the expected effect on warfarin therapy, and what
mechanism is responsible?
A. Increased INR due to CYP450 inhibition by rifampin
B. Decreased INR due to CYP450 induction by rifampin
C. Increased bleeding risk due to additive anticoagulant effect
D. No significant interaction between these agents
Correct Answer: B
Rationale: Rifampin is a potent CYP450 inducer (particularly CYP2C9, CYP3A4, and
CYP1A2) that increases warfarin metabolism, leading to decreased INR and therapeutic
failure. Warfarin dosing must be increased by 30-50% during rifampin therapy and
monitored closely. This is a classic pharmacokinetic drug-drug interaction.
Q4: A drug has a therapeutic index of 2.5. Which statement best describes the clinical
significance of this value?
A. The drug is extremely safe with a wide margin between effective and toxic doses
B. The drug requires careful monitoring due to a narrow margin between effective and
toxic doses
C. The drug has no toxic effects at any dose
D. The drug is ineffective at standard doses
Correct Answer: B
Rationale: The therapeutic index (TD₅₀/ED₅₀) measures drug safety. A low therapeutic
index (<5) indicates a narrow margin between effective and toxic doses, requiring
,careful monitoring (e.g., digoxin, lithium, warfarin, aminoglycosides). A high therapeutic
index (>10) indicates greater safety (e.g., penicillins, most beta-blockers).
Q5: A patient taking phenytoin for seizure control has subtherapeutic drug levels despite
appropriate dosing. The patient recently started taking St. John's Wort for depression.
What is the most likely explanation?
A. St. John's Wort inhibits CYP2C9, decreasing phenytoin metabolism
B. St. John's Wort induces CYP3A4 and P-glycoprotein, increasing phenytoin clearance
C. St. John's Wort displaces phenytoin from albumin binding sites
D. St. John's Wort increases phenytoin absorption from the GI tract
Correct Answer: B
Rationale: St. John's Wort is a potent CYP3A4 and P-glycoprotein inducer that increases
metabolism and clearance of many drugs, including phenytoin, oral contraceptives,
warfarin, and cyclosporine. This causes subtherapeutic levels and treatment failure. It
does not inhibit CYP2C9, displace albumin binding, or increase absorption.
Q6: A 62-year-old male with renal impairment (CrCl 28 mL/min) is prescribed a drug that
is 80% renally excreted unchanged. The normal dose is 500 mg every 12 hours. What is
the most appropriate dose adjustment?
A. Continue 500 mg every 12 hours; renal function does not affect dosing
B. Reduce to 250 mg every 12 hours to prevent accumulation and toxicity
C. Reduce to 500 mg every 24 hours to maintain peak concentrations
D. Increase to 750 mg every 12 hours to compensate for reduced clearance
Correct Answer: B
Rationale: For drugs primarily renally excreted, dose reduction is required when CrCl <30
mL/min. Reducing the dose while maintaining the interval preserves therapeutic peaks
while preventing accumulation and toxicity. Extending the interval may result in
subtherapeutic troughs. Increasing the dose would worsen toxicity.
, Q7: A drug with high first-pass hepatic metabolism is administered sublingually instead
of orally. What is the expected effect on bioavailability?
A. Bioavailability decreases due to altered absorption
B. Bioavailability increases because the drug bypasses hepatic first-pass metabolism
C. Bioavailability remains unchanged regardless of route
D. Bioavailability decreases due to rapid swallowing and GI metabolism
Correct Answer: B
Rationale: Sublingual administration allows direct absorption into the systemic
circulation via the sublingual veins, bypassing hepatic first-pass metabolism. This
significantly increases bioavailability for drugs with high hepatic extraction ratios (e.g.,
nitroglycerin, testosterone). The drug should not be swallowed to maintain this
advantage.
Q8: A patient is a poor metabolizer of CYP2D6. Which drug effect would be most
pronounced if the patient is prescribed codeine for pain?
A. Enhanced analgesic effect due to increased morphine conversion
B. Reduced analgesic effect due to decreased morphine conversion
C. Increased risk of respiratory depression from morphine accumulation
D. No change in analgesic effect because codeine acts directly
Correct Answer: B
Rationale: Codeine is a prodrug that requires CYP2D6-mediated conversion to morphine
for analgesic effect. Poor metabolizers (CYP2D6 *3, *4, *5 alleles) convert minimal
codeine to morphine, resulting in inadequate pain relief. Ultra-rapid metabolizers are at
risk for morphine toxicity and respiratory depression, particularly in children.
Q9: A drug has a volume of distribution (Vd) of 300 L. Which characteristic best
describes this drug?
A. Highly water-soluble with minimal tissue distribution
B. Highly lipophilic with extensive tissue distribution
FINAL 2026/2027 | Care of the Patient Exam | Chamberlain |
Pass Guaranteed - A+ Graded
SECTION 1: Foundations of Advanced Pharmacology (Q1-Q15)
Q1: A 68-year-old male with atrial fibrillation is started on amiodarone. He also takes
simvastatin 80 mg daily. The AGACNP recognizes that amiodarone inhibits CYP3A4 and
CYP2C9. Which adverse effect is most likely to occur from this drug-drug interaction?
A. Rhabdomyolysis from increased simvastatin levels
B. Hyperkalemia from decreased potassium excretion
C. Hypoglycemia from increased insulin sensitivity
D. Thrombocytopenia from bone marrow suppression
Correct Answer: A
Rationale: Amiodarone is a potent CYP3A4 inhibitor that increases simvastatin plasma
levels, significantly increasing the risk of statin-induced myopathy and rhabdomyolysis.
The simvastatin dose should be limited to 20 mg when used with amiodarone.
Amiodarone does not significantly affect potassium excretion, insulin sensitivity, or
platelet production via CYP inhibition.
Q2: A patient receives a drug with a half-life of 6 hours. Approximately how long will it
take to reach steady-state plasma concentration with consistent dosing?
A. 6 hours
B. 12 hours
C. 24 hours
D. 30 hours
,Correct Answer: D
Rationale: Steady-state concentration is typically reached after 4-5 half-lives. With a
6-hour half-life, steady state is achieved in 24-30 hours (4-5 × 6). This principle applies
to most drugs regardless of dosing interval, though loading doses can achieve
therapeutic levels more rapidly.
Q3: A 55-year-old female is prescribed warfarin 5 mg daily. She begins taking rifampin
for tuberculosis treatment. What is the expected effect on warfarin therapy, and what
mechanism is responsible?
A. Increased INR due to CYP450 inhibition by rifampin
B. Decreased INR due to CYP450 induction by rifampin
C. Increased bleeding risk due to additive anticoagulant effect
D. No significant interaction between these agents
Correct Answer: B
Rationale: Rifampin is a potent CYP450 inducer (particularly CYP2C9, CYP3A4, and
CYP1A2) that increases warfarin metabolism, leading to decreased INR and therapeutic
failure. Warfarin dosing must be increased by 30-50% during rifampin therapy and
monitored closely. This is a classic pharmacokinetic drug-drug interaction.
Q4: A drug has a therapeutic index of 2.5. Which statement best describes the clinical
significance of this value?
A. The drug is extremely safe with a wide margin between effective and toxic doses
B. The drug requires careful monitoring due to a narrow margin between effective and
toxic doses
C. The drug has no toxic effects at any dose
D. The drug is ineffective at standard doses
Correct Answer: B
Rationale: The therapeutic index (TD₅₀/ED₅₀) measures drug safety. A low therapeutic
index (<5) indicates a narrow margin between effective and toxic doses, requiring
,careful monitoring (e.g., digoxin, lithium, warfarin, aminoglycosides). A high therapeutic
index (>10) indicates greater safety (e.g., penicillins, most beta-blockers).
Q5: A patient taking phenytoin for seizure control has subtherapeutic drug levels despite
appropriate dosing. The patient recently started taking St. John's Wort for depression.
What is the most likely explanation?
A. St. John's Wort inhibits CYP2C9, decreasing phenytoin metabolism
B. St. John's Wort induces CYP3A4 and P-glycoprotein, increasing phenytoin clearance
C. St. John's Wort displaces phenytoin from albumin binding sites
D. St. John's Wort increases phenytoin absorption from the GI tract
Correct Answer: B
Rationale: St. John's Wort is a potent CYP3A4 and P-glycoprotein inducer that increases
metabolism and clearance of many drugs, including phenytoin, oral contraceptives,
warfarin, and cyclosporine. This causes subtherapeutic levels and treatment failure. It
does not inhibit CYP2C9, displace albumin binding, or increase absorption.
Q6: A 62-year-old male with renal impairment (CrCl 28 mL/min) is prescribed a drug that
is 80% renally excreted unchanged. The normal dose is 500 mg every 12 hours. What is
the most appropriate dose adjustment?
A. Continue 500 mg every 12 hours; renal function does not affect dosing
B. Reduce to 250 mg every 12 hours to prevent accumulation and toxicity
C. Reduce to 500 mg every 24 hours to maintain peak concentrations
D. Increase to 750 mg every 12 hours to compensate for reduced clearance
Correct Answer: B
Rationale: For drugs primarily renally excreted, dose reduction is required when CrCl <30
mL/min. Reducing the dose while maintaining the interval preserves therapeutic peaks
while preventing accumulation and toxicity. Extending the interval may result in
subtherapeutic troughs. Increasing the dose would worsen toxicity.
, Q7: A drug with high first-pass hepatic metabolism is administered sublingually instead
of orally. What is the expected effect on bioavailability?
A. Bioavailability decreases due to altered absorption
B. Bioavailability increases because the drug bypasses hepatic first-pass metabolism
C. Bioavailability remains unchanged regardless of route
D. Bioavailability decreases due to rapid swallowing and GI metabolism
Correct Answer: B
Rationale: Sublingual administration allows direct absorption into the systemic
circulation via the sublingual veins, bypassing hepatic first-pass metabolism. This
significantly increases bioavailability for drugs with high hepatic extraction ratios (e.g.,
nitroglycerin, testosterone). The drug should not be swallowed to maintain this
advantage.
Q8: A patient is a poor metabolizer of CYP2D6. Which drug effect would be most
pronounced if the patient is prescribed codeine for pain?
A. Enhanced analgesic effect due to increased morphine conversion
B. Reduced analgesic effect due to decreased morphine conversion
C. Increased risk of respiratory depression from morphine accumulation
D. No change in analgesic effect because codeine acts directly
Correct Answer: B
Rationale: Codeine is a prodrug that requires CYP2D6-mediated conversion to morphine
for analgesic effect. Poor metabolizers (CYP2D6 *3, *4, *5 alleles) convert minimal
codeine to morphine, resulting in inadequate pain relief. Ultra-rapid metabolizers are at
risk for morphine toxicity and respiratory depression, particularly in children.
Q9: A drug has a volume of distribution (Vd) of 300 L. Which characteristic best
describes this drug?
A. Highly water-soluble with minimal tissue distribution
B. Highly lipophilic with extensive tissue distribution
